Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1021-1040 of 1,738 trials

HIV-1 Treatment: High-Dose Antiretroviral Drugs

We are studying whether high doses of antiretroviral drugs can reduce the hidden HIV-1 reservoir in people living with HIV. This trial will also assess the safety and effects of the treatment on immune markers.

HIV Infection6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious Diseases

Behçet’s Disease Uveitis: Adalimumab vs. Tocilizumab

We are comparing two biologic treatments for severe uveitis in Behçet’s disease to see which one may better improve vision and reduce inflammation. This study will also evaluate the safety of both medications.

Severe Uveitis of Behçet’s Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOphthalmologyRheumatology

Breast Cancer: Palbociclib and Fulvestrant Combination

We are testing a combination of palbociclib and fulvestrant in women with advanced breast cancer who have not responded to prior treatments. The goal is to evaluate its effectiveness and safety for these patients.

Metastatic Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesOncology

BRAF Mutated Melanoma: Encorafenib and Binimetinib with Cemiplimab and Fianlimab

We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.

Melanoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyOncology

Colorectal Cancer: PIPAC Treatment Study

We are testing a new chemotherapy method to prevent cancer spread in patients who have had surgery for high-risk colorectal cancer. This study will help us understand its effectiveness and impact on patients' quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Parkinson's Disease: BIIB122 Treatment Study

We are studying the safety and effects of BIIB122 in people with LRRK2-associated Parkinson's disease. This trial aims to understand how well the treatment engages important biological pathways.

Parkinson's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurology

Paracetamol: Brain Effects Study

We are exploring how paracetamol impacts brain function using advanced imaging techniques. This study aims to better understand its effects on pain management.

Healthy VolunteerEfficacy phase (II)Internal MedicineNeurologyOtolaryngology

Brigatinib for Pediatric and Young Adult ALK+ Cancer

We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.

Anaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

Type 2 Diabetes: Comparing Empagliflozin, Pioglitazone, and Semaglutide

We are studying how different diabetes medications affect fat tissue function in people with type 2 diabetes. This research may help us understand which drug works best for improving health outcomes.

Type 2 Diabetes6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteDiabetologyEndocrinology

Pancreatic Cancer: Trametinib and Hydrochloroquine Study

We are exploring a new treatment combination for patients with metastatic pancreatic cancer to see if it helps improve survival and understand resistance to therapy. This study aims to assess safety and effectiveness while analyzing how the cancer may resist treatment.

Metastatic Pancreatic CancerEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

NK Cell Infusion for Sarcoma in Young Patients

We are testing a new immunotherapy using activated NK cells for children, adolescents, and young adults with refractory sarcomas. The goal is to evaluate its safety and effects after chemotherapy or radiotherapy.

Sarcomas>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

CSL889 for Sickle Cell Disease: A New Treatment

We are studying the safety and effects of CSL889 in adults and adolescents with sickle cell disease during painful vaso-occlusive crises. The goal is to see if it helps speed up recovery compared to a placebo.

Sickle Cell Anemia with Crisis≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Colon Cancer: Dostarlimab with CAPEOX

We are studying a new treatment combining dostarlimab with CAPEOX for people with untreated Stage III colon cancer. The goal is to see if this combination is more effective and safe compared to CAPEOX alone.

Metastatic Colon CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Recurrent Meningioma: [177Lu]Lu-DOTATATE Treatment Study

We are investigating whether [177Lu]Lu-DOTATATE can effectively treat recurrent meningioma compared to standard care. The study will also look at safety and quality of life for participants.

Meningioma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesNeurologyOncology

Kidney Transplantation: Donor Modified Immune Cells

We are studying whether using specially modified immune cells can help patients tolerate their new kidney better than standard treatments. The trial also looks at the safety of this new approach in preventing infections and other complications.

Kidney Transplant>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Mindfulness Training and Oxytocin for Stress Relief

We are studying whether combining oxytocin treatment with mindfulness training can better reduce stress in adults with high stress levels. This trial will measure changes in psychological distress and other related factors.

Psychological Distress≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost Reimbursement

Neurodegenerative Disorders: Tau PET Imaging Study

We are exploring a new imaging method to identify early signs of neurodegenerative diseases in at-risk individuals. The study aims to understand how tau protein relates to cognitive changes and different types of dementia.

Neurodegenerative Diseases>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurology

Peritonitis Treatment: Pentaglobin® Study

We are investigating whether Pentaglobin® can improve organ function and reduce the risk of death in patients recovering from peritonitis. This study looks at changes in health over time after infection control.

SepsisSeptic ShockSeptic Peritonitis3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

BRAF Alterations in Cancer: FORE8394 Treatment Study

We are testing the drug FORE8394 in patients with advanced solid tumors or specific brain tumors that have BRAF alterations. The goal is to see if it can effectively treat these cancers.

BRAF Gene MutationEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

YTB323 for Treatment-Resistant Generalized Myasthenia Gravis

We are studying the safety and effects of YTB323 in patients with treatment-resistant generalized myasthenia gravis. This research aims to understand how the drug works in the body and its potential to improve symptoms.

Myasthenia Gravis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology